Comparison · NCT02387216-sae
Arm A (Experimental): MM-121 in Combination With Docetaxel vs Arm B (Comparator): Docetaxel Alone: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm A (Experimental): MM-121 in Combination With Docetaxel vs Arm B (Comparator): Docetaxel Alone: serious adverse events. Trial comparisons, record NCT02387216-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02387216-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.388 | 0.3 | 0.485 | wilson | |
| Risk in group 2 | 0.306 | 0.195 | 0.445 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0822 | -0.0827 | 0.229 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.27 | 0.78 | 2.06 | log | |
| Odds ratio, group 1 over group 2 | 1.44 | 0.697 | 2.97 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Arm A (Experimental): MM-121 in Combination With Docetaxel than on Arm B (Comparator): Docetaxel Alone | 12.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm A (Experimental): MM-121 in Combination With Docetaxel | MM-121 (Seribantumab, a human monoclonal antibody that targets ErbB3, a cell surface receptor that is activated by the ligand heregulin. Heregulin-driven ErbB3 signaling has been implicated as a mechanism of tumor growth and resistance to targeted, cytotoxic and anti-endocrine therapies. When used in the combination setting, seribantumab is designed to block ErbB3 signaling in order to enhance the anti-tumor effect of a combination therapy partner): 3000 mg fixed dose intravenous (IV) on Day 1 of each 21-day cycle~Docetaxel (approved chemotherapy treatment for non-small cell lung cancer (NSCLC)): 75 mg/m˄2 IV on Day 1 of each 21-day cycle | 40 | 103 | EG000 |
| Group 2 | Arm B (Comparator): Docetaxel Alone | Docetaxel (approved chemotherapy treatment for NSCLC):~75 mg/m˄2 IV on Day 1 of each 21-day cycle | 15 | 49 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From Baseline through to premature study completion up to 3 years, 11 months (02 Jan 2019)
Source ClinicalTrials.gov
Trial
- Title
- A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
- NCT number
- NCT02387216
- Phases
- PHASE2
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, Adenocarcinoma, Heregulin
- Interventions
- MM-121, Docetaxel
- Lead sponsor
- Elevation Oncology
- Results first posted
- 2021-10-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02387216?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02387216-sae